Thursday, November 21, 2019 11:13:27 PM
With all of the class action lawsuits against Lipocine, I doubt they have the money to defend themselves in court to avoid paying judgements, but if they don't pay to defend the lawsuits, they would automatically lose. It's either pay to defend and win, pay to defend and lose, or not pay to defend and lose.
Wouldn't it truly be a better world if the class actions lawsuits sued the FDA, rather than Lipocine? Wouldn't that seem more legitimate an fair? This is yet another example of how backward the world is.
Wouldn't it truly be a better world if the class actions lawsuits sued the FDA, rather than Lipocine? Wouldn't that seem more legitimate an fair? This is yet another example of how backward the world is.
Recent LPCN News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 09:08:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 01:00:16 PM
- Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting • PR Newswire (US) • 05/19/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/18/2026 01:00:24 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 09:00:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:09:00 PM
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 • PR Newswire (US) • 05/07/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 01:05:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:00:59 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/21/2026 09:12:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 09:01:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:05:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 10:27:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 11:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 10:33:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:05:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 01:40:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 01:35:13 PM
- Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression • PR Newswire (US) • 04/02/2026 12:00:00 PM
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 • PR Newswire (US) • 03/10/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 10:13:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 09:05:52 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/26/2026 10:33:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 02:37:58 PM
